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Abstract 
Objective 
People with diabetes frequently develop vascular disease. We investigated the relationship 
between blood 25-hydroxy vitamin D (25OH-D) concentration and vascular disease risk in type 2 
diabetes. 
Research design and methods 
The relationships between blood 25OH-D concentration at baseline and the incidence of 
macrovascular (including myocardial infarction, stroke) and microvascular (retinopathy, 
nephropathy, neuropathy, and amputation) disease were  analysed with Cox proportional-hazards 
models and logistic regression in an observational study of patients in the 5-year Fenofibrate 
Intervention and Event Lowering in Diabetes trial. 
Results 
50% of the patients had low vitamin D concentrations, as indicated by median blood 25OH-D 
concentration of 49nmol/L. These patients with a blood 25OH-D concentration < 50nmol/L had a 
higher cumulative incidence of macrovascular and microvascular events than those with levels ≥ 
50nmol/L. Multivariate analysis, stratified by treatment and adjusted for relevant confounders, 
identified blood 25OH-D concentration as an independent predictor of macrovascular events. A 
50nmol/L difference in blood 25OH-D concentration was associated with a 23% (P=0.007) 
change in risk of macrovascular complications during the study and further adjustments for 
seasonality, hs-CRP and physical activity level had little impact. The unadjusted risk of 
microvascular complications was 18% (P=0.006) higher during the study, though the excess risk 
declined to 11-14% and lost significance with adjustment for HbA1C, seasonality or physical 
activity. 
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Conclusions 
Low blood 25OH-D concentrations are associated with an increased risk of macrovascular and 
microvascular disease events in type 2 diabetes. However, a causal link remains to be 
demonstrated. 
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Diabetes mellitus is among the leading causes of death and affects 347 million people worldwide. 
The WHO expects a 50% increase in deaths from diabetes over the next 10 years, and by 2030 
diabetes mellitus is projected to be the seventh leading cause of death (1). Most major 
complications involve large vessel (macrovascular) or small vessel (microvascular) disease. 
Recent reports have suggested associations between vascular disease (2–5), diabetes (6–8), and 
vitamin D deficiency. Higher rates of cardiovascular disease with lower vitamin D levels have 
also been reported, but most of these studies have been cross-sectional or based on unadjudicated 
endpoints. Rigorous large-scale prospective studies are needed to evaluate the relationship 
between circulating 25 hydroxyvitamin D (25OH-D) concentrations and vascular disease in 
diabetic patients, and more particularly, no large-scale studies have addressed the issue of 
microvascular diseases. 
The FIELD (Fenofibrate Intervention and Event Lowering in Diabetes) study provides a unique 
opportunity to examine the relationship of blood vitamin D concentration with macrovascular and 
microvascular events (9–11). Here we report the relationships between baseline blood 25OH-D 
concentrations and prospective macrovascular and microvascular events in the FIELD cohort. 
Research design and methods 
Study design 
The FIELD trial was a multinational, double-blind, placebo-controlled trial in 63 centres in 
Australia, New Zealand, and Finland. All patients gave written informed consent. The study 
protocol was approved by local and national ethics committees and undertaken in accordance 
with the Declaration of Helsinki and Good Clinical Practice guidelines. 
The study population (Supplemental figure S1) consisted of 9795 participants aged 50–75 years 
with type 2 diabetes mellitus diagnosed according to WHO criteria who were not taking lipid-
modifying therapy at study entry. A detailed description of the study design has been published 
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(12). Patients recruited from hospital clinics and community sources were randomly allocated to 
once-daily micronised fenofibrate 200 mg (Laboratoires Fournier, Dijon, France) or matching 
placebo. Exclusion criteria included renal impairment (blood creatinine >130 μmol/L), known 
chronic liver disease or symptomatic gallbladder disease, and a cardiovascular event within the 3 
months before recruitment. Blood 25OH-D results at baseline were available from 9524 FIELD 
participants (Supplemental figure 1). 
Blood sampling and measurement of 25OH-D 
Fasting blood samples were collected into serum tubes. After clotting, serum was separated and 
frozen on site. Frozen samples were transported to one of two central laboratories, in Adelaide 
(Australia) and Helsinki (Finland), where they were aliquoted and stored at -80°C until analysis. 
For the measurement of 25OH-D, frozen samples were transported to the Department of 
Biochemistry at Royal Prince Alfred Hospital in Sydney (Australia). Only 271 (2.8%) samples 
were unavailable for analysis. Blood 25OH-D was assayed by a chemiluminescence 
immunoassay (DiaSorin Spa, Italy) on a Liaison automated analyser (DiaSorin Spa, Saluggia, 
Italy). This assay detects 25OH-D2 and 25OH-D3 in an equimolar fashion. The lower limit of 
detection with this assay was 10 nmol/L; undetectable concentrations were assigned a value 
midway between this and zero (5 nmol/L). The assay used in this study was a premarket version 
that has been shown to compare closely with higher-order methods, including liquid 
chromatography tandem mass spectrometry (LCMS) and radioimmunoassay (13). In addition, it 
has been shown to have performance identical to that of the current market version of the 
DiaSorin Liaison assay. Assay performance was monitored over time by internal quality-control 
procedures including the use of high- and low-concentration pooled sera. Levels of 25OH-D 
below 65 nmol/L have been associated with rising levels of parathyroid hormone (14). While this 
may imply a broader agreement for the bone-related actions of 25OH-D, cut-off levels for many 
of the other actions of 25OH-D have not been established as yet. In agreement with previous 
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recommendations from the Institute of Medicine, 25 OH-D concentrations < 50 nmol/L were 
deemed to be low for the purposes of this report. 
Assessment of other variables 
Other biomarkers used for adjustment in analysis were measured using standardised routine 
methods as described previously (10). Measurement of high sensitive C-reactive protein (hs-CRP) 
used an automated immune-turbidometric assay from Roche Diagnostics run on a Modular E170 
analyser (Roche Diagnostics, Mannheim, Germany). Baseline physical activity levels were 
recorded in response to a self-reported questionnaire including the categories self-care/home (e.g. 
house work, lawn mowing), occupational (type of work, e.g. sitting, home building), recreation 
(sports) and physical conditioning (aspects of general fitness). All categories were recorded on a 
scale from 1 (very light) to 5 (very heavy) (15). 
Verification of macrovascular and microvascular disease events 
A detailed description of all events and how they were verified has been published elsewhere 
(10,12). Macrovascular events included myocardial infarction, stroke, cardiovascular death, and 
coronary or carotid revascularisation. Incident events were verified by an outcome assessment 
committee masked to study treatment allocation. Incident microvascular events were classified as 
follows: peripheral neuropathy, abnormal monofilament test; nephropathy, urinary 
albumin:creatinine ratio ≥2.5mg/mmol for men and ≥3.5mg/mmol for women; retinopathy, on-
study laser treatment for diabetic retinopathy (including macular oedema); amputation, minor 
amputation without known peripheral vascular disease in the same limb. Measurement of urinary 
albumin excretion and the monofilament test were performed at baseline, at 2 and 5 years, and at 
study close. 
Statistical analysis 
Normally distributed variables were summarised as means and standard deviations, and non-
normally distributed variables as medians and interquartile ranges. Chi-square tests were used to 
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compare categorical variables. For continuous variables, groups were compared using t tests or 
Wilcoxon rank–sum tests if the variables were non-normally distributed. Spearman correlations 
were used for bivariate analysis of continuous variables. 
Prospective associations with incident events during follow-up were assessed using unadjusted 
and adjusted Cox proportional-hazards analysis for macrovascular events, and logistic regression 
for microvascular events (as some of the latter were assessed only at specific time points). 
Analyses were stratified by study treatment allocation and adjusted for baseline event status. 
Adjusted models also included sex, age, diabetes duration, haemoglobin A1C, systolic blood 
pressure, body mass index (BMI), lipids (triglycerides, high-density lipoprotein cholesterol, low-
density lipoprotein cholesterol), smoking, baseline use of oral hypoglycaemics, and baseline use 
of insulin. 
In exploratory analyses, we also adjusted for physical activity score, hs-CRP, and season. For 
each patient, date of sample collection and country of residence (northern or southern 
hemisphere) were used to identify the season at the time of sample collection (winter, spring, 
autumn, summer). Season was then included in the multivariable model as a factor variable. 
As well as vitamin D in the models as a continuous variable (with results reported for increments 
of 50 nmol/L), quartiles of vitamin D were also examined. Cumulative risk curves of 
macrovascular and microvascular events were derived from the Kaplan–Meier method. 
Two sided P values less than 0.05 were considered statistically significant. All analyses used SAS 
(version 9.2) and ACCorD (Analysis of Censored and Correlated Data) software (version 1.6.3). 
Results 
Baseline characteristics 
The study treatment groups were well matched for baseline characteristics, such as age, body 
mass index, smoking habits, blood pressure and duration of diabetes (10). Both groups had 
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similar cardiovascular histories. The use of glucose-lowering and cardiovascular medication was 
as expected for a cohort of people with diabetes and did not differ between the two groups. The 
median 25OH-D concentration in the entire cohort was 49 nmol/L (range 5-196 nmol/L (Figure 
1)) and there was no significant difference between the two groups. Eight percent, 52% and 89 % 
had blood 25OH-D concentrations <25, <50, and <75 nmol/L, respectively. Vitamin D 
supplements were used by 0.1% but only one patient used a dose >700 IU daily. 
In patients who had low vitamin D at baseline (blood 25OH-D <50 nmol/L), cardiovascular 
disease, hypertension, retinopathy, and nephropathy were more prevalent (Table 1). In addition, 
these patients had a higher baseline prevalence of dyslipidaemia and microalbuminuria. On 
average, patients with low 25OH-D also had 0.3% (3 mmol/mol) higher HbA1c, 0.3 mg/L higher 
hs-CRP, and 1.2 kg/m2 higher BMI. There were significantly fewer former and current smokers 
among the participants with low 25OH-D. 
Description of events 
During the 5-year follow-up period, 1250 patients (13.1% of the entire cohort) had at least one 
macrovascular event and 2395 (25.1% of the entire cohort) had at least one microvascular event. 
Most of the affected patients had one or two events during the 5-year follow-up. New or 
worsening nephropathy (1632 or 17.1% of the entire cohort) and new neuropathy (651or 6.8% of 
the entire cohort) were the most common microvascular complications. Retinopathy requiring 
laser surgery and amputations occurred in less than 5% of the entire cohort. 
Prediction of incident macrovascular events by baseline blood 25OH-D 
Blood 25OH-D was an independent predictor of incident macrovascular events over 5 years of 
follow-up. This relationship remained unchanged in multivariable analyses (Table 2). For each 50 
nmol/L difference in baseline blood 25OH-D concentration, the unadjusted risk of incident 
cardiovascular events during follow-up was altered by 20% (95% CI, 5-39%; P=0.01). 
Multivariable adjustment confirmed a significant prospective association between baseline blood 
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25OH-D and incident cardiovascular events with a 23% (95% CI, 6-42%; P=0.007) higher risk 
per 50 nmol/L lower baseline concentration. Exploratory further adjustment for physical activity 
score, hs-CRP or seasonality level did not materially change these relationships (Table 3). The 
association between quartiles of blood 25OH-D and incident macrovascular events is shown in 
Table 2. In the adjusted model, patients in the lowest quartile of blood 25OH-D (<36 nmol/L) 
showed 21% higher risk of macrovascular disease than those in the highest quartile (>63 nmol/L). 
Patients with a low blood 25OH-D concentration (less than the median (50 nmol/L)) had a higher 
cumulative incidence of macrovascular events than those whose concentrations fell above the 
median (Figure 2A). The cumulative incidence of microvascular disease was not significantly 
higher at the prespecified cut-point (Figure 2B), but a higher incidence was evident at levels of 
25OH-D <36 nmol/L. Analysis using this cut-point, which was not pre-specified, revealed that 
the incidence was significantly higher in patients with 25OH-D levels below 36 nmol/L 
(Supplemental Figure 2).  
Prediction of incident microvascular complications by baseline blood 25OH-D during 
follow-up 
Blood 25OH-D was significantly associated with new microvascular complications over 5 years 
of follow-up (Table 2).  Compared with those whose blood 25OH-D concentrations fell above the 
median (50 nmol/L), the lower group had an absolute excess of events during follow-up (Figure 
2). Prospective analysis of incident events during follow-up revealed 18% (95% CI, 5-32%; 
P=0.006) higher unadjusted risk of a microvascular event for each 50 nmol/L difference in  
25OH-D blood concentration, and a 15% (95% CI, 1-30%; P=0.03) higher risk after 
multivariable adjustment. Exploratory further adjustment for HbA1c, physical activity score, or 
seasonality abolished its significance and reduced the incremental risk to 11-12% (not significant, 
Table 3).   
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Discussion 
This large-scale prospective study demonstrates an inverse association between the serum 
concentration of 25OH-D and future macrovascular and microvascular disease which was 
independent of treatment and the duration of diabetes. Higher baseline blood 25OH-D was 
associated with reductions in the risk of macrovascular disease by 20 % and microvascular 
disease by 18% per 50 nmol/L, which, after adjustment for classical risk predictors, including 
HbAIC, became 23 % and 11% (not significant), respectively. 25OH-D levels below 36 nmol/L 
were significantly associated with future microvascular events, but analysis of this cutpoint was 
based on visualization of the distribution of events and was not prespecified. Whilst it raised the 
possibility that more severe 25OH-D depletion may contribute directly to the risk of 
microvascular events, analysis adjusted for HbA1c still fell short of significance (P = 0.07). 
The results are in keeping with cross-sectional (5) and prospective (4) studies showing an inverse 
relationship between 25OH-D and cardiovascular disease. A cross-sectional analysis of data from 
the third National Health and Nutrition Examination Survey (NHANES) showed a higher 
prevalence of vitamin D deficiency in patients with cardiovascular disease than in patients 
without (29.3 vs 21.4 %) (5). In addition, subjects with low 25OH-D had an odds ratio for pre-
existing cardiovascular disease of 1.20 (95 % CI, 1.01-1.36; P=0.03). However, the study was 
cross-sectional and lacked a rigorous verification of cardiovascular disease. In a nested case-
control study including 454 patients with cardiovascular events and 900 matched controls, 
individuals with vitamin D deficiency at baseline had a 10-year relative risk of nonfatal 
myocardial infarction or fatal coronary heart disease of 2.09 (95 % CI, 1.24-3.54; P=0.02 for 
trend) (4). Case-control studies typically overestimate risk, are affected by selection bias and lack 
randomisation. In contrast, FIELD was a prospective, randomised study with 1250 cardiovascular 
events rigorously verified by an independent event review committee. 
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The results of our study expand existing knowledge by showing prospectively in a large cohort 
that low blood 25OH-D is also a risk factor for development of peripheral neuropathy, 
retinopathy, nephropathy, and amputation. Previous cross-sectional studies reported lower 
circulating 25OH-D concentrations in diabetic patients with microvascular disease events (16–
19). However, all these studies were limited by their size and design. In NHANES, for example, 
the diagnosis of peripheral neuropathy is based on self-reported symptoms of neuropathy, such as 
pain, tingling, numbness, or loss of feeling in hands or feet (19). In contrast, Kaur et al. reported a 
higher prevalence of vitamin D deficiency in patients with diabetic retinopathy but found no 
association between vitamin D deficiency and neuropathy or nephropathy (20). 
Potential mechanisms that explain the relationship between vitamin D deficiency and vascular 
disease (microvascular and macrovascular disease) include pancreatic beta-cell dysfunction, 
peripheral insulin resistance, chronic inflammation and endothelial dysfunction. In animal 
models, vitamin D deficiency impairs insulin synthesis (21, 22), possibly via a reduced 
intracellular calcium concentration (23). The final statistical models presented in our study were 
adjusted for indices of glycaemic control, such as glycated haemoglobin, fasting glucose and 
insulin, so beta-cell dysfunction and abnormal glucose homoeostasis may partly explain the 
increased risk of microvascular, but not macrovascular disease, with decreasing blood 
concentrations of 25OH-D.  
Despite the well-established link between immune function and vitamin D (24), reduction in 
blood 25OH-D concentrations may be a nonspecific marker of chronic illness and the 
associations between blood 25OH-D and clinical outcomes may represent reverse causality. In 
our study blood 25OH-D remained a significant predictor of macrovascular and microvascular 
events after adjustment for hs-CRP, a biomarker of chronic inflammation. Recent metanalyses 
failed to find benefits for survival, cardiovascular disease or multiple outcomes (other than 
birthweight) following vitamin D supplementation (25, 26). On the other hand, metanalyses 
12 
which differentiated between D2 and D3 supplementation demonstrated a selective benefit 
following the use of D3 (27, 28).  In the present study, blood 25OH-D measurements reflected the 
concentration of the combination of D2 and D3.  
Sedentary lifestyle characterised by insufficient physical activity is another established risk factor 
for cardiovascular disease and type 2 diabetes. Physical activity may increase blood 25OH-D 
concentrations as a consequence of an associated increase in sunlight exposure. Sarcopoenia and 
reduced muscle strength are associated with low blood 25OH-D concentrations (29) and a 
number of recent publications support the presence of the vitamin D receptor (VDR) in numerous 
tissues including skeletal muscle (30, 31). The study by Autier detected a beneficial effect of 
lower doses of vitamin D among elderly women in whom mobility was more likely to be reduced 
(25). Adjustment for activity level affected the inverse association between vitamin D and 
microvascular, but not macrovascular, outcomes.  
Direct effects of vitamin D on vessel function are another explanation for the relationship 
between vitamin D and vascular disease (33-34). However, Wang and DeLuca recently reported 
that the VDR is not expressed in cardiac myocytes and vascular smooth muscle cells (35), which 
challenges the hypothesis of direct vascular effects of vitamin D. In fact, it appears that most of 
the antibodies used to identify VDR in these previous studies detect proteins other than VDR, and 
may have led to false-positive results. In summary, existing data are insufficient to establish the 
mechanism responsible for the increased risk of vascular events in people with low vitamin D. 
However, the present results suggest that the relationship between serum 25OH-D and 
microvascular complications is partially due to the surrogacy for the effects of diabetes, season 
and activity. 
The median blood 25OH-D concentration in the FIELD cohort was 49 nmol/L, indicating that 
more than 50 % of the participants patients had low 25OH-D . Furthermore, 25% had blood 
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25OH-D concentrations of 36 nmol/L or less. This supports previous reports showing a high 
prevalence of vitamin D deficiency in the general population and in elderly individuals 
worldwide (36–38). Considering the relationship of vitamin D with common chronic diseases, the 
high prevalence of vitamin D deficiency has socioeconomic implications, affecting individual 
patients and health care systems. 
The main strengths of the study are its prospective and randomised design, the large number of 
participants and the high number of verified microvascular and macrovascular events. Blood 
25OH-D was measured with a well characterised latest generation chemiluminescence 
immunoassay that compares well with higher-order methods, such as liquid chromatography 
tandem mass spectrometry (13). This is important, as the performance of vitamin D assays varies 
substantially (13,39). 
 Our study also has some limitations. Fenofibrate treatment is known to reduce cardiovascular 
and microvascular events and may have biased our results. However, the effect of blood 25OH-D 
on microvascular and macrovascular risk was similar in the placebo and the fenofibrate groups, 
and no heterogeneity was detected. Individuals with low 25OH-D had a higher prevalence of 
microvascular and macrovascular disease at baseline which predisposes them to a higher event 
rate during the study period, but there was no difference in the association seen among people 
with and without prior macrovascular and microvascular disease. 
These relationships raise the question whether vitamin D supplementation can lower the risk of 
vascular events (25, 26). Few prospective intervention studies with sufficient statistical power 
have addressed this question. Both the Womens Health Initiative Study, which followed over 
36 000 women, and the RECORD trial, which studied over 5000 patients, failed to show 
cardiovascular benefit (40, 41), but metanalysis suggests the formulation of vitamin D may be 
important (27, 28).  
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The findings also raise the question whether vitamin D supplementation can lower the risk of 
diabetic microvascular complications, possibly via an effect on HbA1C. Short-term administration 
of a supraphysiologic dose of vitamin D does not affect insulin sensitivity (42). In contrast, 
supplementation with 2000 IU of cholecalciferol for 16 weeks has been reported to improve ß-
cell function (43). A recent meta-analysis suggested that vitamin D administration did not 
improve HbA1c or overall mortality (25). Together with our results, the negative outcomes of 
vitamin D supplementation studies highlight the importance of endogenous vitamin D synthesis 
and the need for further research into the role of vitamin D deficiency. 
In conclusion, this study provides prospective evidence for serum vitamin D as a risk marker for 
future vascular events. The association of vitamin D with macrovascular disease was not 
explained by associated effects on β-cell function, glucose homeostasis, physical activity or 
seasonality whilst the novel relationship between serum vitamin D and microvascular disease was 
attributable to these covariates. The mechanisms underlying these relationships require further 
research and the results of large-scale supplementation trials. 
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Table 1: Baseline characteristics by serum vitamin D concentration (≥50 vs <50) 
Characteristic 
Total vitamin D 
≥50 nmol/L 
(n=4560) 
Total vitamin D <50 
nmol/L 
(n=4964) 
General characteristics   
Assigned fenofibrate 2266 (49.7%) 2495 (50.3%) 
Male 3235 (70.9%) 2732 (55.0%)* 
Age at visit 1 (years, mean[SD]) 62.5 (6.8) 62.0 (7.0)* 
Diabetes duration (years, median[IQR]) 5 (2–9) 5 (2–10)* 
Body-mass index (kg/m2, median[IQR]) 29.2 (26.5–32.6) 30.4 (27.1–34.5)* 
Blood pressure, systolic (mmHg, mean[SD]) 139.8 (15.0) 141.2 (15.7)* 
Blood pressure, diastolic (mmHg, mean[SD]) 81.7 (8.3) 82.4 (8.7)* 
Exsmoker or current smoker 2849 (62.5%) 2860 (57.6%)* 
Clinical history   
Previous cardiovascular disease 947 (20.8%) 1120 (22.6%)* 
Peripheral vascular disease 341 (7.5%) 400 (8.1%) 
Coronary revascularisation (CABG or PTCA) 195 (4.3%) 154 (3.1%)* 
History of hypertension 2498 (54.8%) 2907 (58.6%)* 
History of diabetic retinopathy 345 (7.6%) 448 (9.0%)* 
Neuropathy (self-reported) 574 (12.6%) 789 (15.9%)* 
Laboratory data   
Total cholesterol (mmol/L, mean[SD]) 4.98 (0.71) 5.09 (0.70)* 
LDL cholesterol (mmol/L, mean[SD]) 3.05 (0.66) 3.07 (0.64) 
HDL cholesterol (mmol/L, mean[SD]) 1.08 (0.25) 1.11 (0.27)* 
Triglycerides (mmol/L, median[IQR]) 1.68 (1.31–2.24) 1.79 (1.38–2.40)* 
HbA1c (%,median[IQR]) 6.7 (6.0–7.6) 7.0 (6.2–8.0)* 
HbA1c (mmol/mol) 50 (42–60) 53 (44–64) 
Plasma creatinine (umol/L, mean[SD]) 79.1 (15.5) 76.3 (15.9)* 
Dyslipidaemia 1624 (35.6%) 1982 (39.9%)* 
Urine ACR, microalbuminuria 921 (20.3%) 1128 (22.8%)* 
Urine ACR, macroalbuminuria 185 (4.1%) 210 (4.2%) 
Hight sensitive C-reactive protein (mg/L, 
median[IQR]) 
2.6 (1.3–5.5) 2.9 (1.3–6.3)* 
Baseline cardiovascular medication   
Any antithrombotic 1432 (31.4%) 1547 (31.2%) 
Any warfarin 119 (2.6%) 114 (2.3%) 
Aspirin or other antithrombotic without warfarin 1313 (28.8%) 1433 (28.9%) 
21 
Characteristic 
Total vitamin D 
≥50 nmol/L 
(n=4560) 
Total vitamin D <50 
nmol/L 
(n=4964) 
   
Angiotensin II receptor antagonist 241 (5.3%) 273 (5.5%) 
ACE inhibitor 1460 (32.0%) 1741 (35.1%)* 
Beta blocker 602 (13.2%) 784 (15.8%)* 
Calcium antagonist 878 (19.3%) 956 (19.3%) 
Diuretic 658 (14.4%) 795 (16.0%)* 
Nitrate 230 (5.0%) 303 (6.1%)* 
Baseline blood-glucose-lowering medication   
Diet 1309 (28.7%) 1220 (24.6%)* 
Oral hypoglycaemic agent 2724 (59.7%) 2955 (59.5%) 
Any insulin 527 (11.6%) 789 (15.9%)* 
Vitamin D supplementation   
Vitamin D supplements 3 (0.1%) 4 (0.1%) 
Vitamin D <700 IU daily 3 (0.1%) 3 (0.1%) 
Vitamin D ≥700 IU daily 0 (0.0%) 1 (0.0%) 
Calcium supplements 123 (2.7%) 137 (2.8%) 
* P<0.05 
ACR, albumin/creatinine ratio 
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Table 2: Association between serum vitamin D concentration (25OH-D) and new events during follow-up 
 
    Unadjusted model Adjusted model 
 
n Events % OR or HR (95% CI) P 
P for 
trend OR or HR (95% CI) P 
P for 
trend 
Macrovascular          
25OH-D (nmol/L) (per 50 nmol/L difference) 9524 1250 13.12 1.20 (1.05–1.39)† 0.01  1.23 (1.06–1.42) † 0.007  
          
Quartile      0.02   0.01 
 >63 2354 293 12.45 1.00†   1.00†   
 50–63 2206 269 12.19 0.99 (0.84–1.17)† 0.89  1.00 (0.84–1.18) † 0.97  
 36–<50 2680 353 13.17 1.07 (0.91–1.24)† 0.42  1.10 (0.94–1.28) † 0.25  
 <36 2284 335 14.67 1.19 (1.02–1.40)† 0.03  1.21 (1.03–1.43) † 0.02  
         
Microvascular      
 
 
   
25OH-D (nmol/L) (per 50 nmol/L difference) 9524 2395 25.15 1.18 (1.05–1.32)† 0.006  1.11 (0.98–1.26) † 0.11  
Quartile     0.008   0.13 
 >63 2354 568 24.13 1.00†   1.00†   
 50–63 2206 526 23.84 0.98 (0.86–1.13)† 0.82  0.95 (0.82–1.09) † 0.46  
 36–<50 2680 679 25.34 1.07 (0.94–1.21)† 0.32  1.02 (0.89–1.16) † 0.81  
 <36 2284 622 27.23 1.18 (1.03–1.34)† 0.02  1.10 (0.95–1.26) † 0.19  
* Odds ratio, adjusted for age, sex, diabetes duration, haemoglobin A1c, systolic blood pressure, body mass index, lipids (triglycerides, high- and low-density lipoprotein 
cholesterol), smoking, baseline use of oral hypoglycaemics, and baseline use of insulin. 
† Hazard ratio, stratified by treatment and adjusted for prior macrovascular disease, age, sex, diabetes duration, haemoglobin A1c, systolic blood pressure, body mass index, 
lipids (triglycerides, high- and low-density lipoprotein cholesterol), smoking, baseline use of oral hypoglycaemic agents, and baseline use of insulin. 
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Table 3: Exploratory models investigating the impact of HbA1c, hs-CRP, physical activity and seasonal variability on the association between serum 
25OH-D and new events during follow-up 
 
  Adjusted model 
New events during follow-up  OR or HR (95% CI) P 
Macrovascular    
25OH-D (nmol/L) (per 50 nmol/L difference) Adjusted for all* + HbA1c 1.23 (1.06–1.42)  0.007 
 Adjusted for all* + hs-CRP 1.26 (1.09-1.46) 0.002 
 Adjusted for all* + physical activity 1.21 (1.04-1.42) 0.02 
 Adjusted for all* + seasonal variability 1.24 (1.06-1.44) 0.006 
Microvascular    
25OH-D (nmol/L) (per 50 nmol/L difference) Adjusted for all* + HbA1c 1.11 (0.98–1.26)  0.11 
 Adjusted for all* + hs-CRP 1.14 (1.01-1.29) 0.04 
 Adjusted for all* + physical activity 1.11 (0.98-1.27) 0.11 
 Adjusted for all* + seasonal variability 1.12 (0.99-1.27) 0.08 
 
* Stratified by treatment and adjusted for age, sex, diabetes duration, systolic blood pressure, body mass index, lipids (triglycerides, high- and low-density lipoprotein 
cholesterol), smoking, baseline use of oral hypoglycaemics, and baseline use of insulin. 
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Figure legends 
Figure 1 
Distribution of baseline blood 25-hydroxy vitamin D (25OH-D) concentrations in the FIELD 
study. 
Figure 2 
Effects of serum concentration of 25-hydroxy vitamin D (25OH-D) on incident events. A. 
Cumulative risk of macrovascular events for patients above and below the median 25OH-D 
concentration. B. Cumulative risk of microvascular events for patients above and below the 
median 25OH-D concentration.  Complete microvascular event data were available at 2 years, 5 
years, and at end-of-study follow-up. 
0 10 20 30 40 50 60 70 80 90 100110 120130 140150160170180190200
0
5
10
15
20
25
%
Serum  25OH-D (nmol/L) 
C
um
ul
at
iv
e 
ris
k 
(%
)
0
5
10
15
20
Years after randomization 
0 1 2 3 4 5 6
P=0.03
Numbers at risk
4964       4817 4638 4481 4321 2430       779
4560       4453 4300 4166 4016 2097 734
< 50 nmol/L
≥ 50 nmol/L
C
um
ul
at
iv
e 
ris
k 
(%
)
0
10
20
30
40
50
4964      4831 4532 4160 4079 2264 691
4560      4478 4227 3941       3848 1923 640
P=0.06
A
B
Years after randomization 
0 1 2 3 4 5 6
Numbers at risk
< 50 nmol/L
≥ 50 nmol/L
13900 
screened
9795 
randomized
2625 ineligible
10 died
93 compliance problems
85 suspected drug reaction
1334 withdrew consent
9524 measured for 
vitamin D at baseline
1250 on-study macrovascular
events
2395 on-study microvascular events
5206 without prior macrovascular or 
microvascular disease
1132 with prior macrovascular disease only
2251 with prior microvascular disease only
935 with prior macrovascular and 
microvascular disease
271 samples not available
Supplemental figure S1
Patient enrolment and progress through the study.
Serum 25-hydroxy vitamin D: a predictor of 
macrovascular and microvascular complications in 
patients with type 2 diabetes
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Effects of serum concentration of 25OH-D <36 nmol/L or ≥36 nmol/L on
incident microvascular disease events (complete microvascular event
data were available at 2 years, 5 years, and at end-of-study follow-up).
